IL-17F Induces IL-6 Via TAK1-NFκB Pathway in Airway Smooth Muscle Cells
Overview
Infectious Diseases
Authors
Affiliations
Introduction: Interleukin (IL)-17F plays a critical role in the pathophysiology of asthma. However, the precise role of IL-17F in airway smooth muscle cells (ASMCs) and its regulatory mechanisms remain to be defined. Therefore, we sought to investigate the expression of IL-6 by IL-17F and the involvement of transforming growth factor β-activated kinase 1 (TAK1) and nuclear factor (NF)-κB by in ASMCs.
Methods: ASMCs were cultured in the presence or absence of IL-17F. The expression of IL-6 gene and protein was analyzed using real-time PCR and ELISA, and the activation of TAK1 and NF-κB was detected by Western blotting. The effect of TAK1 inhibitor 5Z-7-oxozeaenol and NF-κB inhibitor BAY 11-7082 on the expression of IL-6 was investigated. Finally, the short interfering RNAs (siRNAs) targeting TAK1 and a subunit of NF-κB, p65 were transfected into ASMCs.
Results: The expression of IL-6 gene and protein was significantly induced by IL-17F. IL-17F activated TAK1 and NF-κB in ASMCs. Transfection of siRNAs targeting TAK1 abolished IL-17F-induced phosphorylation of p65. Both 5Z-7-oxozeaenol and BAY 11-7082 significantly inhibited IL-17F-induced IL-6 production in a dose-dependent manner. Similarly, transfection of the cells with siRNAs targeting TAK1 and p65 inhibited the expression of IL-6.
Conclusions: Collectively, these results provided evidence supporting the potential importance of the Th17-ASMCs crosstalk via the IL-17F-IL-6 axis in airway inflammation and as a candidate pharmacological target for airway inflammatory diseases such as asthma.
Vinnakota J, Biavasco F, Schwabenland M, Chhatbar C, Adams R, Erny D Nat Cancer. 2024; 5(8):1227-1249.
PMID: 38741011 DOI: 10.1038/s43018-024-00764-7.
Dai Y, Nasehi F, Winchester C, Foley A Biol Open. 2023; 12(6).
PMID: 37272627 PMC: 10261723. DOI: 10.1242/bio.059881.
Miki H, Kiosses W, Manresa M, Gupta R, Sethi G, Herro R J Allergy Clin Immunol. 2022; 151(4):976-990.e5.
PMID: 36473503 PMC: 10081945. DOI: 10.1016/j.jaci.2022.11.016.
Kadowaki M, Sato K, Kamio H, Kumagai M, Sato R, Nyui T J Inflamm Res. 2021; 14:7021-7034.
PMID: 34955648 PMC: 8694576. DOI: 10.2147/JIR.S326964.
Regulatory T Cells in Severe Persistent Asthma in the Era of Monoclonal Antibodies Target Therapies.
Bergantini L, Cameli P, dAlessandro M, Vietri L, Perruzza M, Pieroni M Inflammation. 2019; 43(2):393-400.
PMID: 31853715 DOI: 10.1007/s10753-019-01157-0.